UC patients achieve symptomatic improvement ‘as early as day 2’ with etrasimod (Healio)

A post hoc analysis of the ELEVATE UC trials showed a “rapid treatment effect” with early symptomatic response in patients treated with etrasimod for ulcerative colitis. The findings were presented by Marla C. Dubinsky, MD, a pediatric gastroenterologist at Mount Sinai Kravis Children’s Hospital, at the ACG Annual Scientific Meeting. The study revealed that more patients treated with etrasimod compared to placebo achieved clinical remission and response during the 12-week induction period for both ELEVATE UC 52 and ELEVATE UC 12.

Key takeaways from the study include:

1. Patients treated with etrasimod achieved symptomatic response by day 2 and remission by day 11.
2. Stool frequency normalization and rectal bleeding remission were significant at days 3 and 15, respectively.
3. In the phase 3 ELEVATE UC trial program, within the first 28 days, there were clinically relevant symptomatic improvements seen in patients treated with etrasimod vs. placebo as early as day 2.